Sinotherapeutics, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sinotherapeutics, Inc.

Why is Sinotherapeutics, Inc. ?

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of 21.00% and Operating profit at 19.25% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times
The company has been able to generate a Return on Equity (avg) of 10.64% signifying low profitability per unit of shareholders funds

With a fall in Net Sales of -12.82%, the company declared Very Negative results in Sep 25

NET SALES(Q) At CNY 111.86 MM has Fallen at -12.82%
INTEREST COVERAGE RATIO(Q) Lowest at 2,713,996.62
OPERATING PROFIT(Q) Lowest at CNY 13.01 MM

Below par performance in long term as well as near term

Along with generating -10.11% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sinotherapeutics, Inc. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sinotherapeutics, Inc.

-11.32%

0.41

32.54%

China Shanghai Composite

15.45%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

21.00%

EBIT Growth (5y)

19.25%

EBIT to Interest (avg)

54.21

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.57

Sales to Capital Employed (avg)

0.32

Tax Ratio

9.90%

Dividend Payout Ratio

21.80%

Pledged Shares

Institutional Holding

ROCE (avg)

11.52%

ROE (avg)

10.64%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.71

EV to EBIT

36.43

EV to EBITDA

29.24

EV to Capital Employed

7.33

EV to Sales

8.02

PEG Ratio

1.41

Dividend Yield

ROCE (Latest)

20.11%

ROE (Latest)

9.15%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 130.95 MM

-22What is not working for the Company

NET SALES(Q)

At CNY 111.86 MM has Fallen at -12.82%

INTEREST COVERAGE RATIO(Q)

Lowest at 2,713,996.62

OPERATING PROFIT(Q)

Lowest at CNY 13.01 MM

RAW MATERIAL COST(Y)

Grown by 24.23% (YoY

OPERATING PROFIT MARGIN(Q)

Lowest at 11.63 %

PRE-TAX PROFIT(Q)

Lowest at CNY 17.39 MM

NET PROFIT(Q)

Lowest at CNY 17.88 MM

EPS(Q)

Lowest at CNY 0.04

Here's what is working for Sinotherapeutics, Inc.

Operating Cash Flow

Highest at CNY 130.95 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Here's what is not working for Sinotherapeutics, Inc.

Net Sales

At CNY 111.86 MM has Fallen at -12.82%

over average net sales of the previous four periods of CNY 128.31 MM

MOJO Watch

Near term sales trend is very negative

Net Sales (CNY MM)

Interest Coverage Ratio

Lowest at 2,713,996.62

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Operating Profit

Lowest at CNY 13.01 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite negative

Operating Profit (CNY MM)

Pre-Tax Profit

At CNY 17.39 MM has Fallen at -47.76%

over average net sales of the previous four periods of CNY 33.3 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Operating Profit Margin

Lowest at 11.63 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CNY 17.39 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

Lowest at CNY 17.88 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

Net Profit

At CNY 17.88 MM has Fallen at -39.98%

over average net sales of the previous four periods of CNY 29.78 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS

Lowest at CNY 0.04

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Raw Material Cost

Grown by 24.23% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales